J Am Coll Cardiol 2008;51:538–45 Acute and Late Outcomes of Unprotected Left Main Stenting in Comparison With Surgical Revascularization Pawel E. Buszman,

Slides:



Advertisements
Similar presentations
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Advertisements

CABG VS Multi Vessel PCI Hasanat Sharif MD FRCS Chief of Cardiorthoracic Surgery Aga Khan University Hospital.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
FFR vs Angiography for Multivessel Evaluation
ARTS I & II Keith D Dawkins Southampton University Hospital.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
PCI VS CABG JOURNAL REVIEW
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Lesson 4 What is the treatment for Coronary Artery Disease?
Ischemic heart disease. Indications and methods of surgical treatment. Surgery department №2.
Call for CASES Staged PCI in a patient with multivessel coronary disease disqualified from CABG. Pawel Buszman, MD, FESC, FSCAI Marcin Debinski, MD Krzysztof.
REVASCULARIZATION Vs MEDICAL THERAPY IN STABLE CAD
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Coronary Artery Disease in Diabetic Patients, Different from Non-diabetics?
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park, MD, PhD, University.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Disclosures The presenter has no financial involvement with the product or competing products being discussed. The presenter received travel and lodging.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Left Main Stem Intervention Trials & Registries Keith D. Dawkins MD FRCP FACC Southampton University Hospital UK.
David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Lianglong Chen MD PhD FACC
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prospective Application of Pre-Defined Intravascular.
Multivessel Coronary Artery Disease
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk of Stroke With Coronary Artery Bypass Graft.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Treatment of Protected and Unprotected.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
S Ten Tse and Sensibility!
Total Occlusion Study of Canada (TOSCA-2) Trial
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
On behalf of the PRECOMBAT Investigators
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.
Nat. Rev. Cardiol. doi: /nrcardio
Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
The American College of Cardiology Presented by Dr. A. Abazid
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

J Am Coll Cardiol 2008;51:538–45 Acute and Late Outcomes of Unprotected Left Main Stenting in Comparison With Surgical Revascularization Pawel E. Buszman, Stefan R. Kiesz, Andrzej Bochenek, Ewa Peszek-Przybyla, Iwona Szkrobka, Marcin Debinski, Bozena Bialkowska, Dariusz Dudek, Agata Gruszka, Aleksander Zurakowski, Krzysztof Milewski, Miroslaw Wilczynski, Lukasz Rzeszutko, Piotr Buszman, Jan Szymszal, Jack L. Martin, Michal Tendera Oxford, United Kingdom; Los Angeles, California; Buffalo, New York Greenville and Durham, North Carolina; Atlanta, Georgia; Dallas, Texas Leuven, Belgium; and Hamilton, Ontario, Canada

Introduction Drug-eluting stents do not improve survival reduce myocardial infarction lack of cost-effectiveness increased risk of stent thrombosis ACC/AHA guidelines for LMS stenosis PCI is a class III indication (i.e., that the procedure is generally not effective and may even be harmful) in those who are otherwise eligible for CABG European Society of Cardiology stenting for unprotected left main disease should only be considered in the absence of other revascularization options In comparison with BMS

Introduction in a 2004 survey of interventions for LMS stenosis 29% of European and 18% of U.S. patients The advent of coronary stents lowered the incidence of abrupt vessel closure DES decreased the risk of ULMCA in-stent restenosis compare acute and late clinical end points, functional status, and LV function at 1 year following stent-supported PCI or CABG for ULMCA disease in a prospective randomized trial

Figure 1 Experimental Design of the Study

Materials and Methods Exclusion criteria acute myocardial infarction total occlusion of left main comorbid conditions coronary anatomic considerations that increased the surgical risk to a Euroscore of 8 or more stroke or transient ischemic attack within 3 months Renal dysfunction contraindication to antiplatelet therapy LV function evaluation Before and 12 months after the index procedure Treadmill stress tests; 1, 3, 6, 12 months after procedure

Materials and Methods Percutaneous revascularization “culotte” technique with kissing balloon angioplasty ( no crush stent technique) 3.8 mm BMS glycoprotein IIb/IIIa blockers Surgical revascularization All but 1 operation; standard cardiopulmonary bypass One patient underwent off-pump CABG Left internal mammary artery grafts; 72% radial artery grafts; 9% Primary end point The change in LVEF assessed by 2D echocardiography 12 months after the index intervention Secondary end points 30-day and 1-year MAE and MACCE

Table 1 Baseline Characteristics of the Study Groups

Table 2 Detailed List of MAE in CABG and PCI Group During the First Year After the Procedure

Figure 2 LVEF in PCI and CABG Groups at Baseline and After 12 Months

Figure 3 CCS Functional Class at Baseline and Follow-Up

Figure 4 Results of Treadmill Stress Tests After PCI and CABG

Figure 5 Survival After PCI and CABG

Figure 6 MACCE-Free Survival After PCI and CABG

Discussion 3 important anatomical features of LM Left main stem stenosis occurs as an isolated lesion in only 6% to 9% of patients, whereas over 70% to 80% of patients also have multivessel CAD thereby potentially enabling more complete coronary revascularization with CABG than with stenting Most LMS stenoses (40% to 94%) occur in the distal segment of the artery and extend into the proximal coronary arteries; such bifurcated or trifurcated lesions have a high risk of restenosis while acute occlusion at this site can have catastrophic consequences Morphologically, around one-half of LMS lesions have significant calcification

Current Results of CABG for LMS Stenosis

Eight Studies of PCI Using BMS in LMS

DES in LMS

Conclusions stent-supported PCI have favorable early outcomes in comparison with CABG At 1 year, LVEF improved only in the PCI group Freedom from MACCE was comparable after more than 2 years of follow-up, and there was a trend for better survival in the PCI group.